Inventor · disambiguated record
Shi-Lung Lin
Also filed as: LIN SHI · LIN SHI-LUNG
26 granted patents·23 pending applications·229 citations·filing 1993–2024
95Inventor score
Files withLIN SHI-LUNG24MELLO BIOTECHNOLOGY INC5UNIV SOUTHERN CALIFORNIA5EPICLONE INC3MELLO BIOTECH TAIWAN CO LTD2
Top patents by PatentIndex Score
49 records- 0191US6197554B1Method for generating full-length cDNA library from single cellsFiled 1998·Granted Mar 6, 2001·163 cites·44 claims
- 0286US8372969B2RNA interference methods using DNA-RNA duplex constructsUNIV SOUTHERN CALIFORNIA·Filed 2010·Granted Feb 12, 2013·5 cites·13 claims
- 0384US9399773B2Production and extraction of MicroRNA precursor as drug for cancer therapyLIN SHI-LUNG·Filed 2013·Granted Jul 26, 2016·5 cites·13 claims
- 0481US9879263B2Use of microRNA precursors as drugs for inducing CD34-positive adult stem cell expansionMELLO BIOTECHNOLOGY INC·Filed 2016·Granted Jan 30, 2018·2 cites·15 claims
- 0581US9387251B2Sugar alcohol-based compositions for delivering nucleic acid-based drugs in vivo and in vitroLIN SHI-LUNG·Filed 2014·Granted Jul 12, 2016·3 cites·30 claims
- 0679US8609831B2RNA-mediated gene modulationLIN SHI-LUNG·Filed 2003·Granted Dec 17, 2013·5 cites·12 claims
- 0772US9422559B2Production and utilization of a novel anti-cancer drug in therapyLIN SHI-LUNG·Filed 2013·Granted Aug 23, 2016·1 cites·9 claims
- 0871US9783811B2Inducible gene expression composition for using eukaryotic pol-2 promoter-driven transcription in prokaryotes and the applications thereofMELLO BIOTECHNOLOGY INC·Filed 2014·Granted Oct 10, 2017·1 cites·22 claims
- 0971US9637747B2Inducible gene expression composition for using eukaryotic pol-2 promoter-driven transcription in prokaryotes and the applications thereofMELLO BIOTECHNOLOGY INC·Filed 2014·Granted May 2, 2017·1 cites·13 claims
- 1071US9567591B2Generation of human embryonic stem-like cells using intronic RNALIN SHI-LUNG·Filed 2008·Granted Feb 14, 2017·1 cites·32 claims
- 1171US9453219B2Cosmetic designs and products using intronic RNALIN SHI-LUNG·Filed 2007·Granted Sep 27, 2016·1 cites·11 claims
- 1271US2025019709A1Novel oxo-rna compositions and the related applications thereofLIN SHI LUNG·Filed 2024·Application pending·0 cites
- 1369US2024189235A1Cationic lipids and uses thereofMELLO BIOTECH TAIWAN CO LTD·Filed 2023·Application pending·0 cites
- 1468US2025115932A1Induced cytoplasmic ivt (icivt)-like composition and the related vaccine medicine designs thereofLIN SHI LUNG·Filed 2023·Application pending·0 cites
- 1567US9956196B2Use of monosaccharide-like glycylated sugar alcohol compositions for designing and developing anti-diabetic drugsLIN SHI LUNG·Filed 2014·Granted May 1, 2018·0 cites·12 claims
- 1667US5449736AWater soluble phosphorylated polysiloxanesRES FOUNDATION OF THE STATE OF·Filed 1993·Granted Sep 12, 1995·11 cites·2 claims
- 1767US2024093286A1Novel Replicase Cycling Reaction (RCR) and the Related RdRP-Binding Site Designs ThereofLIN SHI LUNG·Filed 2023·Application pending·0 cites
- 1866US11326164B2Trimethylglycylglycerin compositions and their use in developing anti-cancer drugs and RNA vaccinesWJWU & LYNN INSTITUTE FOR STEM CELL RES·Filed 2020·Granted May 10, 2022·1 cites·23 claims
- 1966US2023295627A1Novel Replicase Cycling Reaction (RCR) and the Related SamRNA Designs ThereofLIN SHI LUNG·Filed 2023·Application pending·0 cites
- 2065US9394538B2Development of universal cancer drugs and vaccinesLIN SHI-LUNG·Filed 2010·Granted Jul 19, 2016·1 cites·27 claims
- 2163US2023099592A1Novel replicase cycling reaction (rcr)LIN SHI LUNG·Filed 2022·Application pending·0 cites
- 2261US2023242958A1Synthetic rna fragment and its uses for rna-dependent amplificationMELLO BIOTECH TAIWAN CO LTD·Filed 2023·Application pending·0 cites
- 2359US7662791B2Gene silencing using mRNA-cDNA hybridsUNIV SOUTHERN CALIFORNIA·Filed 2001·Granted Feb 16, 2010·2 cites·7 claims
- 2459US2022396778A1Novel RNA Composition and Production Method for Use in iPS Cell GenerationLIN SHI LUNG·Filed 2022·Application pending·0 cites
- 2557US2008242627A1Novel rna interference methods using dna-rna duplex constructsUNIV SOUTHERN CALIFORNIA·Filed 2007·Application pending·0 cites
- 2656US10370658B2Composition and method of using miR-302 precursors as anti-cancer drugs for treating human lung cancerLIN SHI LUNG·Filed 2017·Granted Aug 6, 2019·0 cites·20 claims
- 2756US2015031871A1RNA-Mediated Gene ModulationUNIV SOUTHERN CALIFORNIA·Filed 2013·Application pending·0 cites
- 2854US9907773B2Use of novel monosaccharide-like glycylated sugar alcohol compositions for designing and developing anti-diabetic drugsLIN SHI LUNG·Filed 2016·Granted Mar 6, 2018·0 cites·15 claims
- 2954US2020165607A1Composition and method of using mir-302 precursors as anti-cancer drugs for treating human lung cancerLIN SHI LUNG·Filed 2019·Application pending·0 cites
- 3053US8895525B2Preventing hyaluronan-mediated tumorigenetic mechanisms using intronic RNAsYING SHAO-YAO·Filed 2008·Granted Nov 25, 2014·0 cites·8 claims
- 3153US2013210120A1Inducible Gene Expression Composition for Using Eukaryotic Pol-2 Promoter-Driven Transcription in Prokaryotes and the Applications ThereofLIN SHI-LUNG·Filed 2012·Application pending·0 cites
- 3251US2017342418A1Use of microrna precursors as drugs for inducing cd34-positive adult stem cell expansionLIN SHI-LUNG·Filed 2017·Application pending·0 cites
- 3350US2009203141A1Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant RNA agentsLIN SHI-LUNG·Filed 2009·Application pending·0 cites
- 3449US2004106566A1RNA-splicing and processing-directed gene silencing and the relative applications thereofFiled 2003·Application pending·0 cites
- 3549US2020071700A1Composition and method of using mir-302 precursors as drugs for treating alzheimer's diseasesLIN CHIH LI·Filed 2019·Application pending·0 cites
- 3648US11624067B2In-vitro induction of adult stem cell expansion and derivationLIN SHI LUNG·Filed 2018·Granted Apr 11, 2023·0 cites·16 claims
- 3748US10519440B2Composition and method of using miR-302 precursors as drugs for treating Alzheimer's diseasesMELLO BIOTECHNOLOGY INC·Filed 2016·Granted Dec 31, 2019·0 cites·15 claims
- 3847US6130040AMethod for generating directly covalent bonding between interstrand nucleotidesFiled 1998·Granted Oct 10, 2000·6 cites·49 claims
- 3946US5928872ASubtractive hybridization with covalently binding homologyFiled 1997·Granted Jul 27, 1999·6 cites·60 claims
- 4045US2013252339A1Microrna-induced es-like cells and uses thereofUNIV SOUTHERN CALIFORNIA·Filed 2013·Application pending·0 cites
- 4145US2004087526A1Therapeutically useful compositions of DNA-RNA hybrid duplex constructsFiled 2003·Application pending·0 cites
- 4245US2006228800A1Novel Transgenic Methods Using intronic RNALIN SHI-LUNG·Filed 2006·Application pending·0 cites
- 4344US2003022318A1Method for thermocycling amplification of nucleic acid sequences and the generation of related peptides thereofEPICLONE INC·Filed 2001·Application pending·0 cites
- 4441US2003104401A1Gene silencing using sense DNA and antisense RNA hybrid constructsEPICLONE INC·Filed 2002·Application pending·0 cites
- 4540US6015676AMethod for knocking out gene transcripts by covalently binding of an anti-sense probeEPICLONE INC·Filed 1998·Granted Jan 18, 2000·11 cites·53 claims
- 4639US5871927ANucleotide analog-containing hybrid subtraction with sequentially enzymatic digestionFiled 1997·Granted Feb 16, 1999·3 cites·53 claims
- 4738US2016289682A1Production and utilization of a novel anti-cancer drug in therapyLIN SHI-LUNG·Filed 2016·Application pending·0 cites
- 4835US10196662B2Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursorsMELLO BIOTECHNOLOGY INC·Filed 2015·Granted Feb 5, 2019·0 cites·8 claims
- 4932US2020318110A1A composition and method of using mir-302 precursors as anti-cancer drugs for treating human lung cancerLIN SHI LUNG·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Shi-Lung Lin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →